Results from the study continue to demonstrate the transformative potential of zimislecel with consistent and durable patient benefit – ...

Company positioned to initiate multiple Phase 1 clinical trials in 2025 for ART-101 and additional novel radiopharmaceutical assets – ...

SAN DIEGO, CA, USA I June 20, 2025 I Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based ...

With unmatched executional momentum and differentiated programs, Candid Therapeutics is defining a new future in immunology through its commitment to TCEs in autoimmune diseases. Additional trial ...

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo ...

BOSTON, MA, USA & CAMBRIDGE, UK I June 19, 2025 I Cycle Pharmaceuticals announced that the FDA has approved HARLIKU (nitisinone) Tablets for the reduction ...

In-vitro lab results confirmed that the Company’s cell targeting nanoparticles successfully entered cancer cells and avoided non-cancerous cells ...

COPENHAGEN, Denmark I June 18, 2025 I Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development ...

CAMBRIDGE, MA, USA I June 18, 2025 I Biogen Inc. (Nasdaq: BIIB) announced the initiation of dosing in the BRAVE study, a global Phase 3 clinical trial. The ...

BOSTON, MA, USA and SHANGHAI, China I June 18, 2025 I Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule ...

HONG KONG, China I June 19, 2025 I Immuno Cure BioTech ("Immuno Cure"), a clinical-stage biotechnology group based in Hong Kong Science Park, is pleased to ...

Combination of World Leading Epitranscriptomics and AI-Driven Automation Aims to Accelerate Development of Cancer Therapies That Halt Metastasis ...